IMUNON Reports Improved Median Overall Survival with IMNN-001 in Advanced Ovarian Cancer Treatment

IMUNON reported updated Phase 2 data from the OVATION 2 trial, showing a median overall survival increase from 11.1 months to 14.7 months in women with newly diagnosed advanced ovarian cancer treated with IMNN-001. Patients receiving PARP inhibitor therapy in addition to IMNN-001 and standard of care chemotherapy demonstrated a median increase in OS of 24.2 months. Enrollment in IMUNON's Phase 3 pivotal trial remains ahead of plan, supported by strong interest from investigators and the medical community.